BPC-157 vs TB-500: When to Use Each Recovery Peptide
Both are healing peptides, both used by athletes — but the mechanisms and best-fit injuries are different. Here's how clinicians choose between them.
BPC-157 and TB-500 are the two most commonly prescribed healing peptides. They are often discussed interchangeably, but the underlying biology and best-fit indications differ.
BPC-157 mechanism
Body Protection Compound-157 is a synthetic peptide derived from a protective protein found in gastric juice. Its primary actions involve promoting angiogenesis (new blood vessel formation), upregulating growth factor signaling (VEGF, FGF), and protecting endothelial integrity. The animal literature is extensive; the bulk of clinical evidence in humans is observational.
TB-500 (Thymosin Beta-4 fragment)
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in cell migration and tissue repair. It upregulates actin (a structural cellular protein) and accelerates the migration of progenitor cells into damaged tissue. Animal models show benefit in cardiac and musculoskeletal injury.
Where BPC-157 shines
GI-related healing (gastric and intestinal injury, IBD-adjacent symptoms), tendon and ligament injury, and chronic localized inflammation. It is the more commonly used peptide for orthopedic recovery in the U.S.
Where TB-500 shines
Larger soft-tissue injuries, muscle tears, and systemic recovery support after intense training cycles. Its mechanism favors situations where cell migration into a wide injury bed is the rate-limiting step.
How they're combined
Many clinical protocols pair the two for serious injuries: BPC-157 250–500 mcg daily for localized tissue effect, plus TB-500 2–2.5 mg twice weekly for the migration-and-remodeling phase. This stacking is observational practice, not randomized-trial supported.
What the evidence does not yet show
Both peptides lack large randomized human trials. The mechanism is well-characterized in animal and cell models; the clinical evidence in humans is largely observational and anecdotal. Patients should understand this and clinicians should disclose it.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy. Curr Pharm Des. 2018;24:1962-1973.— Current Pharmaceutical Design, 2018.
- 2.Goldstein AL et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11:421-429.— Trends in Molecular Medicine, 2005.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
